- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01894919
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72_28 study.
This study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72_28 study.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Bajcsi Ut 32
-
Debrecen, Bajcsi Ut 32, Hungary, 4025
- Site 34, General Pediatric Practice Somorjai
-
-
Csongradi Sgt 63
-
Szeged, Csongradi Sgt 63, Hungary, 6723
- Site 35, Praxis Dr Eva Kovacs
-
-
Debreceni Utca 10-14
-
Szeged, Debreceni Utca 10-14, Hungary, 6723
- Site 36, General Practice Dr Edit Oszlacs
-
-
Honved Utca 2
-
Bordany, Honved Utca 2, Hungary, 6795
- Site 37, Praxis Dr Julianna Kovacs
-
-
Kando Kalman Utca 1
-
Miskolc, Kando Kalman Utca 1, Hungary, 3534
- Site 31, General Practice Dr Olga Fekete
-
-
Poth Iren U 80
-
Budapest, Poth Iren U 80, Hungary, 1188
- Site 40, General Pediatric Practice Hacsek
-
-
Selyemret U. 1.
-
Miskolc, Selyemret U. 1., Hungary, 3527
- Site 30, General Practice Dr Simko
-
-
Szent Istvan U 10
-
Nyiregyhaza, Szent Istvan U 10, Hungary, 4400
- Site 33, General Pediatric Practice Ujhelyi
-
-
Szentharomsag Ter 10
-
Csongrad, Szentharomsag Ter 10, Hungary, 6640
- Site 42, Praxis Dr Eszter Bari
-
-
-
-
-
Almeria, Spain, 04007
- Site 15
-
Almeria, Spain, 04120
- Site 16
-
Barcelona, Spain, 08195
- Site 20
-
Madrid, Spain, 28041
- Site 17
-
Madrid, Spain, 28935
- Site 18
-
Pontevedra, Spain, 36002
- Site 13
-
Santiago de Compostela, Spain, 15706
- Site 10
-
Sevilla, Spain, 41014
- Site 14
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For naïve subjects newly enrolled:
Healthy infants and children according to the following age groups:
- Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The age window is defined as the first day the subject turns 35 months of age up to the day before the subject turns 48 months of age),
- Healthy subjects 4 to 7 years of age (only applicable to group L) (The age window is defined as the first day the subject turns 4 years of age up to the day before the subject turns 8 years of age).
- Healthy subjects 8 to 12 years of age (only applicable to group M) (The age window is defined as the first day the subject turns 8 years of age up to the day before the subject turns 13 years of age).
- for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
- for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
- in good health as determined by medical history, physical examination, clinical judgment of the investigator.
For Subjects who participated in the V72_28 study (Follow-on Subjects):
- for whom a parent/legal guardian has given written informed consent after the nature of the study has been explained;
- for whom a parent/legal guardian confirmed availability for the visit scheduled in the study;
- in good health as determined by medical history, physical examination, clinical judgment of the investigator
- who have completed the vaccination course in the V72_28 study and have received their last vaccination 24 to 36 months before enrollment in V72_28E1
Exclusion Criteria:
For naïve subjects newly enrolled:
- History of any serogroup B meningococcal vaccine administration;
- Previous known or suspected disease caused by N. meningitidis;
- Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization;
- History of severe allergic reaction after previous vaccinations or hypersensitivity to any component of the vaccine;
- Pregnancy or nursing (breastfeeding) mothers;
- Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, congenital sterility or sexual abstinence are considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry;
Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from (for example):
- Receipt of any chronic immunosuppressive therapy
- Receipt of any chronic immunostimulants
- Immune deficiency disorder, or known HIV infection
- History of seizure, any progressive neurological disease or Guillain Barré Syndrome (exception: one self-limited febrile seizure is acceptable).
- Known bleeding diathesis or any condition that may be associated with a prolonged bleeding time.
- Subject's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
- Intent to participate in another clinical study during this study.
- Family members and household members of study staff;
- History or any illness/condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or pose additional risk to the subjects due to participation in the study.
- Any significant chronic infection.
- Any serious chronic or progressive disease according to judgment of the investigator (e.g. neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
For Subjects who participated in the V72_28 study (Follow-on Subjects):
Exclusion criteria are the same as for naïve subjects, with the exception of criterion 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2H3H511_V
In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively.
The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
|
|
No Intervention: 2H3H511_NV
In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively.
These subjects were evaluated only for persistence.
|
|
Experimental: 3H5_11_V
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively.
These subjects received a 4th dose of Bexsero® vaccine in the present study.
|
|
No Intervention: 3H5_11_NV
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively.
These subjects were evaluated only for persistence.
|
|
Experimental: 68_11_V
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively.
These subjects received a 4th dose of Bexsero® vaccine in the present study.
|
|
No Intervention: 68_11_NV
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively.
These subjects were evaluated only for persistence.
|
|
Experimental: 02_2_5_V
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart.
These subjects received a 3rd dose of Bexsero® vaccine in the present study.
|
|
No Intervention: 02_2_5_NV
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart.
These subjects were evaluated only for persistence.
|
|
Experimental: 02_6_10_V
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart.
These subjects received a 3rd dose of Bexsero® vaccine in the present study.
|
|
No Intervention: 02_6_10_NV
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart.
These subjects were evaluated only for persistence.
|
|
Experimental: NAIVE 123
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
|
|
Experimental: NAIVE_4A
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
|
|
Experimental: NAIVE_4B
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains
Time Frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
|
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA). |
24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
|
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains
Time Frame: At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects
|
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.
|
At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects
|
The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains
Time Frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
|
The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.
|
24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
|
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.
Time Frame: At Day 1 in this study over one month after the completion of the vaccination course in the parent study
|
The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.
|
At Day 1 in this study over one month after the completion of the vaccination course in the parent study
|
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.
Time Frame: At Day 1 in this study over visit 1 in the vaccination course in the parent study
|
The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.
|
At Day 1 in this study over visit 1 in the vaccination course in the parent study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.
Time Frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
|
The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
|
At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
|
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.
Time Frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
|
The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
|
At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
|
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.
Time Frame: One month after booster vaccination (day 31)/24-36 months (Visit 1)
|
The percentage of subjects with a four-fold rise in hSBA titers 1 month after receiving Bexsero® booster vaccination in this study to pre vaccination at visit 1 (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
|
One month after booster vaccination (day 31)/24-36 months (Visit 1)
|
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study
Time Frame: From post primary visit in the parent study to visit 2 in this extension study
|
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination (visit 2) in this study to post primary visit in the parent study V72_28(1 month after last vaccination in the parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
|
From post primary visit in the parent study to visit 2 in this extension study
|
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.
Time Frame: From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study
|
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination in this study to pre primary visit in parent study V72_28 (Visit 1).
This outcome measure was analysed only for subjects belonging to groups 02_2_5_V and 02_6_10_V
|
From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study
|
The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Time Frame: At Visit 1 and one month post booster vaccination (Day 31)
|
The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.
|
At Visit 1 and one month post booster vaccination (Day 31)
|
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Time Frame: At Day 31 versus Day 1
|
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.
|
At Day 31 versus Day 1
|
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
Time Frame: Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study
|
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination in this study versus 1 month post last vaccination visit (post-primary vaccination visit) in parent study V72_28.
|
Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study
|
Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination
Time Frame: At Baseline and One month post second vaccination (Day 61)
|
The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.
|
At Baseline and One month post second vaccination (Day 61)
|
Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.
Time Frame: At Baseline and One month post second vaccination (Day 61)
|
The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.
|
At Baseline and One month post second vaccination (Day 61)
|
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.
Time Frame: One month post second vaccination (Day 61)
|
The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.
|
One month post second vaccination (Day 61)
|
The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.
Time Frame: At Baseline and One month post second vaccination (Day 61)
|
The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.
|
At Baseline and One month post second vaccination (Day 61)
|
The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.
Time Frame: At one month after receiving second vaccination (Day 61) versus baseline (Day 1)
|
The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.
|
At one month after receiving second vaccination (Day 61) versus baseline (Day 1)
|
Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
Time Frame: From day 1 (6 hr) through day 7 after vaccination
|
The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receiving Bexsero® booster vaccine in the present study.
|
From day 1 (6 hr) through day 7 after vaccination
|
Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.
Time Frame: From day 1 (6 hr) through day 7 after vaccination
|
The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
|
From day 1 (6 hr) through day 7 after vaccination
|
Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
Time Frame: From day 1 (6 hr) through day 7 after vaccination
|
Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.
|
From day 1 (6 hr) through day 7 after vaccination
|
Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.
Time Frame: From day 1(6 hr) through day 7 after vaccination
|
The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
|
From day 1(6 hr) through day 7 after vaccination
|
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.
Time Frame: From day 1 through day 7 after any vaccination
|
The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.
|
From day 1 through day 7 after any vaccination
|
Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.
Time Frame: Throughout the entire study period (up to 2 months)
|
The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.
|
Throughout the entire study period (up to 2 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Meningococcal Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- V72_28E1
- 2012-000657-30 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisSpain, Italy, United Kingdom, Czech Republic
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisKorea, Republic of
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisUnited States, Canada
-
Novartis VaccinesNovartisCompletedMeningococcal Disease | Meningococcal MeningitisUnited States
-
NovartisNovartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisAustralia, Canada
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisChile, Colombia, Panama
Clinical Trials on Bexsero® vaccine (1 dose at study month zero)
-
Poitiers University HospitalCompleted
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Centre Hospitalier Universitaire de... and other collaboratorsUnknownAllograft | Haemopoietic Stem Cell TransplantationFrance
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
Instituto Nacional de Salud Publica, MexicoNational Council of Science and Technology, Mexico; Universidad Nacional Autonoma...Completed
-
Xiamen Innovax Biotech Co., LtdJiangsu Province Centers for Disease Control and PreventionCompleted
-
PfizerCompleted
-
Shanghai Municipal Center for Disease Control and...Shanghai Institute Of Biological ProductsUnknown
-
SanofiCompletedInfluenza | Myxovirus InfectionUnited States
-
CureVacCompleted
-
The Jackson LaboratoryNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingAging | Influenza Vaccine | Vaccine Response | Dendritic CellUnited States